SCHEMBL6910698

SCHEMBL6910698

O=C(O)CCNC(=O)c1ccc(C(=O)C(=CC(=O)c2ccc(Cl)cc2)c2ccc(Cl)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.48
TSHR P16473 1/20 0.48
NFKB1 P19838 1/20 0.48
MAOB P27338 1/20 0.48
MEN1 O00255 1/20 0.47
BLM P54132 1/20 0.47
PMP22 Q01453 1/20 0.47
KMT2A Q03164 1/20 0.47
GCG P01275 3/20 0.47
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
GAA P10253 3/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
MAPK1 P28482 1/20 0.44
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2664956 1.00 CYP1A2 (0.48) CYP1A2TSHRNFKB1MAOBMEN1
SCHEMBL2647595 0.94 NPC1 (0.49) CYP1A2TSHRNFKB1MAOBMEN1
SCHEMBL2647592 0.94 NPC1 (0.49) CYP1A2TSHRNFKB1MAOBMEN1
SCHEMBL2647438 0.93 GCG (0.54) MEN1KMT2AGCGGAAHDAC3
SCHEMBL2647432 0.93 GCG (0.54) MEN1KMT2AGCGGAAHDAC3
SCHEMBL2647121 0.87 SERPINE1 (0.44) MEN1BLMKMT2AGCGHDAC1
SCHEMBL2646582 0.87 SERPINE1 (0.44) MEN1BLMKMT2AGCGHDAC1
SCHEMBL2646577 0.87 SERPINE1 (0.44) MEN1BLMKMT2AGCGHDAC1
SCHEMBL2647127 0.87 SERPINE1 (0.44) MEN1BLMKMT2AGCGHDAC1
SCHEMBL5625471 0.83 CYP1A2 (0.66) CYP1A2TSHRNFKB1MAOBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6762318-B2 CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION NOVO NORDISK A/S (DK) 2004-07-13 US disclosed
US-20030236292-A1 Stimulant releasing glucose from liver cells; antidiabetic agents PFIZER INC 2003-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236292-A1 Stimulant releasing glucose from liver cells; antidiabetic agents GPR119, GLP1R, GIPR CYP1A2 2522/4885TSHR 99/4885NFKB1 2678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.